Janus Henderson Amends Altimmune Stake Filing
Ticker: ALT · Form: SC 13G/A · Filed: Feb 12, 2024 · CIK: 1326190
| Field | Detail |
|---|---|
| Company | Altimmune, Inc. (ALT) |
| Form Type | SC 13G/A |
| Filed Date | Feb 12, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, investor-update
TL;DR
**Janus Henderson Group plc just re-affirmed its stake in Altimmune, Inc. via an amended 13G/A.**
AI Summary
Janus Henderson Group plc, a major investment firm, filed an amended SC 13G/A on February 12, 2024, indicating their ownership of Altimmune, Inc. Common Stock as of December 31, 2023. This filing, an amendment to a previous one, signals that Janus Henderson continues to hold a significant, though not necessarily new, stake in Altimmune. For investors, this matters because it shows a large institutional investor maintains confidence in Altimmune, potentially signaling stability or future growth prospects for the stock.
Why It Matters
This filing confirms a major institutional investor, Janus Henderson Group plc, continues to hold a position in Altimmune, Inc., which can influence market perception and investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine update from an institutional investor and does not indicate any immediate negative or highly volatile event.
Analyst Insight
A smart investor would note that a large institutional investor like Janus Henderson Group plc continues to hold Altimmune stock, suggesting ongoing institutional interest. However, without knowing the exact change in their stake (increase or decrease), it's difficult to draw strong conclusions. Further investigation into the previous 13G filing would be needed to understand the change in ownership percentage.
Key Players & Entities
- Janus Henderson Group plc (company) — the reporting person and institutional investor
- Altimmune, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- February 12, 2024 (date) — the filing date of the SC 13G/A amendment
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as indicated by 'FORM TYPE: SC 13G/A' and 'Amendment No.: 1*'.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is Janus Henderson Group plc, as stated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JANUS HENDERSON GROUP PLC'.
What is the 'Subject Company' whose securities are being reported?
The 'Subject Company' is Altimmune, Inc., as identified under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Altimmune, Inc.' and 'Name of Issuer: ALTIMMUNE, INC.'.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 31, 2023, as explicitly stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' next to '[X] Rule 13d-1(b)'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 12, 2024 regarding Altimmune, Inc. (ALT).